New clinically relevant, orthotopic mouse models of human chondrosarcoma with spontaneous metastasis

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Clark, Jonathan C M ^a   Akiyama, Toru ^a   Dass, Crispin R ^a   Choong, Peter F M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GELATINASE A; GELATINASE B; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CELL PROLIFERATION; CHONDROSARCOMA; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG METASTASIS; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PERIOSTEUM; SARCOMA CELL; TIBIA; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 77953920798     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-20     Document Type: Article

References (49)

1. Björnsson J, McLeod RA, Unni KK, Ilstrup DM, Pritchard DJ. Primary chondrosarcoma of long bones and limb girdles. Cancer 1998, 83:2105-2119. 10.1002/(SICI)1097-0142(19981115)83:10<2105::AID-CNCR9>3.0.CO;2-U, 9827715.
2. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999, 81:326-338. 10.1302/0301-620X.81B5.9588, 10199270.
3. Bruns J, Elbracht M, Niggemeyer O. Chondrosarcoma of bone: an oncological and functional follow-up study. Ann Oncol 2001, 12:859-864. 10.1023/A:1011162118869, 11484965.
4. Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am 2001, 83-A:1630-1642.
5. Johnson S, Tetu B, Ayala AG, Chawla SP. Chondrosarcoma with additional mesenchymal component (dedifferentiated chondrosarcoma). I. A clinicopathologic study of 26 cases. Cancer 1986, 58:278-286. 10.1002/1097-0142(19860715)58:2<278::AID-CNCR2820580213>3.0.CO;2-6, 3719521.
6. York JE, Berk RH, Fuller GN, Rao JS, Abi-Said D, Wildrick DM, Gokaslan ZL. Chondrosarcoma of the spine: 1954 to 1997. Journal of neurosurgery 1999, 90:73-78.
7. Terek RM, Schwartz GK, Devaney K, Glantz L, Mak S, Healey JH, Albino AP. Chemotherapy and P-glycoprotein expression in chondrosarcoma. J Orthop Res 1998, 16:585-590. 10.1002/jor.1100160510, 9820282.
8. Clark JC, Dass CR, Choong PF. Development of chondrosarcoma animal models for assessment of adjuvant therapy. ANZ J Surg 2009, 79:327-336. 10.1111/j.1445-2197.2009.04884.x, 19566512.
9. Klenke FM, Abdollahi A, Bertl E, Gebhard MM, Ewerbeck V, Huber PE, Sckell A. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer 2007, 7:49. 10.1186/1471-2407-7-49, 1832206, 17367541.
10. Hong P, Taylor SM, Trites JR, Bullock M, Nasser JG, Hart RD. Chondrosarcoma of the head and neck: report of 11 cases and literature review. J Otolaryngol Head Neck Surg 2009, 38:279-285.
11. Dass CR, Ek ET, Contreras KG, Choong PF. A novel orthotopic murine model provides insights into cellular and molecular characteristics contributing to human osteosarcoma. Clin Exp Metastasis 2006, 23:367-380. 10.1007/s10585-006-9046-6, 17187230.
12. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer gene therapy 2007, 14:616-626. 10.1038/sj.cgt.7701044, 17479108.
13. Dass CR, Friedhuber AM, Khachigian LM, Dunstan DE, Choong PF. Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic model. Cancer Biol Ther 2008, 7:1033-1036. 10.1158/1535-7163.MCT-07-0179, 18414033.
14. Dass CR, Choong PF. uPAR mediates anticancer activity of PEDF. Cancer Biol Ther 2008, 7:1262-1270. 10.4161/cbt.7.8.6265, 18487955.
15. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 2005, 22:319-329. 10.1007/s10585-005-0365-9, 16170668.
16. Phung MW, Dass CR. In-vitro and in-vivo assays for angiogenesis-modulating drug discovery and development. J Pharm Pharmacol 2006, 58:153-160. 10.1211/jpp.58.2.0001, 16451742.
17. Berlin O, Samid D, Donthineni-Rao R, Akeson W, Amiel D, Woods VL. Development of a novel spontaneous metastasis model of human osteosarcoma transplanted orthotopically into bone of athymic mice. Cancer research 1993, 53:4890-4895.
18. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001, 107:789-800. 10.1016/S0092-8674(01)00597-9, 11747814.
19. Takeuchi T, Hisanaga M, Nagao M, Ikeda N, Fujii H, Koyama F, Mukogawa T, Matsumoto H, Kondo S, Takahashi C, et al. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer. Clin Cancer Res 2004, 10:5572-5579. 10.1158/1078-0432.CCR-03-0656, 15328199.
20. Kunisada T, Miyazaki M, Mihara K, Gao C, Kawai A, Inoue H, Namba M. A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. Int J Cancer 1998, 77:854-859. 10.1002/(SICI)1097-0215(19980911)77:6<854::AID-IJC10>3.0.CO;2-1, 9714054.
21. Kudawara I, Araki N, Myoui A, Kato Y, Uchida A, Yoshikawa H. New cell lines with chondrocytic phenotypes from human chondrosarcoma. Virchows Arch 2004, 444:577-586. 10.1007/s00428-004-1020-6, 15118855.
22. Kenan S, Steiner GC. Experimental transplantation of the Swarm rat chondrosarcoma into bone: radiological and pathological studies. J Orthop Res 1991, 9:445-451. 10.1002/jor.1100090317, 2010849.
23. Grimaud E, Damiens C, Rousselle AV, Passuti N, Heymann D, Gouin F. Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 2002, 17:1103-1111.
24. Ho L, Stojanovski A, Whetstone H, Wei QX, Mau E, Wunder JS, Alman B. Gli2 and p53 cooperate to regulate IGFBP-3- mediated chondrocyte apoptosis in the progression from benign to malignant cartilage tumors. Cancer Cell 2009, 16:126-136. 10.1016/j.ccr.2009.05.013, 19647223.
25. Rüther U, Komitowski D, Schubert FR, Wagner EF. c-fos expression induces bone tumors in transgenic mice. Oncogene 1989, 4:861-865.
26. Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S, Iyer AP. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 1996, 105:91-103. 10.1016/0304-3835(96)04274-7, 8689637.
27. Mankin HJ, Fondren G, Hornicek FJ, Gebhardt MC, Rosenberg AE. The use of flow cytometry in assessing malignancy in bone and soft tissue tumors. Clinical orthopaedics and related research 2002, 95-105. 10.1097/00003086-200204000-00014, 11953601.
28. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 2005, 576:22-38.
29. Gailani MR, Stahle-Backdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, Unden AB, Dean M, Brash DE, Bale AE, Toftgard R. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996, 14:78-81. 10.1038/ng0996-78, 8782823.
30. Clark JC, Thomas DM, Choong PF, Dass CR. RECK--a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007, 26:675-683. 10.1007/s10555-007-9093-8, 17828469.
31. Eisenberg I, Hochner H, Sadeh M, Argov Z, Mitrani-Rosenbaum S. Establishment of the genomic structure and identification of thirteen single-nucleotide polymorphisms in the human RECK gene. Cytogenet Genome Res 2002, 97:58-61. 10.1159/000064042, 12438739.
32. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA. Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. Clinical orthopaedics and related research 2000, 291-303. 10.1097/00003086-200007000-00038, 10906887.
33. Kim DW, Kim KO, Shin MJ, Ha JH, Seo SW, Yang J, Lee FY. siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells. Mol Cancer 2009, 8:28. 10.1186/1476-4598-8-28, 2689171, 19445670.
34. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992, 3:65-71.
35. Ayala G, Liu C, Nicosia R, Horowitz S, Lackman R. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol 2000, 31:341-346. 10.1016/S0046-8177(00)80248-8, 10746677.
36. McGough RL, Aswad BI, Terek RM. Pathologic neovascularization in cartilage tumors. Clin Orthop Relat Res 2002, 76-82. 10.1097/00003086-200204000-00011, 11953598.
37. Lin C, McGough R, Aswad B, Block JA, Terek R. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 2004, 22:1175-1181. 10.1016/j.orthres.2004.03.002, 15475194.
38. Takahashi C, Sheng Z, Horan TP, Kitayama H, Maki M, Hitomi K, Kitaura Y, Takai S, Sasahara RM, Horimoto A, et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:13221-13226. 10.1073/pnas.95.22.13221, 23764, 9789069.
39. Dong Z, Bonfil RD, Chinni S, Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, et al. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. The American journal of pathology 2005, 166:1173-1186. 1602391, 15793297.
40. Blavier L, Delaisse JM. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995, 108(Pt 12):3649-3659.
41. Nakagawa M, Kaneda T, Arakawa T, Morita S, Sato T, Yomada T, Hanada K, Kumegawa M, Hakeda Y. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000, 473:161-164. 10.1016/S0014-5793(00)01520-9, 10812066.
42. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Kodama H. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 1999, 190:293-298. 10.1084/jem.190.2.293, 2195572, 10432291.
43. Rucker M, Roesken F, Vollmar B, Menger MD. A novel approach for comparative study of periosteum, muscle, subcutis, and skin microcirculation by intravital fluorescence microscopy. Microvasc Res 1998, 56:30-42. 10.1006/mvre.1998.2077, 9683561.
44. Chanavaz M. Anatomy and histophysiology of the periosteum: quantification of the periosteal blood supply to the adjacent bone with 85Sr and gamma spectrometry. J Oral Implantol 1995, 21:214-219.
45. Vigorita VJ. Orthopaedic Pathology. 2008, Philadelphia, USA: Lippincott Williams & Wilkins, 2.
46. Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int 2005, 76:146-153. 10.1007/s00223-004-0068-2, 15549636.
47. Chaabane S, Bouaziz MC, Drissi C, Abid L, Ladeb MF. Periosteal chondrosarcoma. AJR Am J Roentgenol 2009, 192:W1-6. 10.2214/AJR.08.1159, 19098166.
48. Papagelopoulos PJ, Galanis EC, Mavrogenis AF, Savvidou OD, Bond JR, Unni KK, Sim FH. Survivorship analysis in patients with periosteal chondrosarcoma. Clinical orthopaedics and related research 2006, 448:199-207. 10.1097/01.blo.0000194684.40624.a8, 16826117.
49. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am 2009, 91:1063-1072. 10.2106/JBJS.H.00416, 19411454.